Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 143

1.

Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats.

Kiss K, Csonka C, Pálóczi J, Pipis J, Görbe A, Kocsis GF, Murlasits Z, Sárközy M, Szűcs G, Holmes CP, Pan Y, Bhandari A, Csont T, Shamloo M, Woodburn KW, Ferdinandy P, Bencsik P.

Pharmacol Res. 2016 Nov;113(Pt A):62-70. doi: 10.1016/j.phrs.2016.08.013.

PMID:
27521836
2.

A dimeric peptide with erythropoiesis-stimulating activity uniquely affects erythropoietin receptor ligation and cell surface expression.

Verma R, Green JM, Schatz PJ, Wojchowski DM.

Exp Hematol. 2016 Aug;44(8):765-769.e1. doi: 10.1016/j.exphem.2016.04.015.

PMID:
27174804
3.

RHEX, a novel regulator of human erythroid progenitor cell expansion and erythroblast development.

Verma R, Su S, McCrann DJ, Green JM, Leu K, Young PR, Schatz PJ, Silva JC, Stokes MP, Wojchowski DM.

J Exp Med. 2014 Aug 25;211(9):1715-22. doi: 10.1084/jem.20130624. Erratum in: J Exp Med. 2015 Jun 1;212(6):971.

PMID:
25092874
4.

Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration.

Woodburn KW, Fong KL, Wilson SD, Sloneker S, Strzemienski P, Solon E, Moriya Y, Tagawa Y.

Drug Metab Dispos. 2013 Apr;41(4):774-84. doi: 10.1124/dmd.112.048033.

PMID:
23318685
5.

Peginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events.

Green JM, Leu K, Worth A, Mortensen RB, Martinez DK, Schatz PJ, Wojchowski DM, Young PR.

Exp Hematol. 2012 Jul;40(7):575-87. doi: 10.1016/j.exphem.2012.02.007. Erratum in: Exp Hematol. 2014 Sep;42(9):838.

PMID:
22406924
6.

Silica as a matrix for encapsulating proteins: surface effects on protein structure assessed by circular dichroism spectroscopy.

Calabretta PJ, Chancellor MC, Torres C, Abel GR, Niehaus C, Birtwhistle NJ, Khouderchah NM, Zemede GH, Eggers DK.

J Funct Biomater. 2012 Aug 2;3(3):514-27. doi: 10.3390/jfb3030514.

PMID:
24955630
7.

Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats.

Woodburn KW, Holmes CP, Wilson SD, Fong KL, Press RJ, Moriya Y, Tagawa Y.

Xenobiotica. 2012 Jul;42(7):660-70. doi: 10.3109/00498254.2011.649310.

PMID:
22188389
8.

Novel p38α mitogen-activated protein kinase inhibitor shows analgesic efficacy in acute postsurgical dental pain.

Tong SE, Daniels SE, Black P, Chang S, Protter A, Desjardins PJ.

J Clin Pharmacol. 2012 May;52(5):717-28. doi: 10.1177/0091270011405496.

PMID:
21659629
9.

Genotoxic assessment and toxicity evaluation of peginesatide in CByB6F1 hybrid mice.

Woodburn KW, Schatz PJ, Wilson S, Fong KL, Wagner VO, Gudi R, Krsmanovic L, Paranjpe M, Shah SA.

Drug Chem Toxicol. 2011 Jul;34(3):240-9. doi: 10.3109/01480545.2010.510140.

PMID:
21649477
10.

Erythropoiesis equivalence, pharmacokinetics and immune response following repeat hematide administration in cynomolgus monkeys.

Woodburn KW, Schatz PJ, Fong KL, Beaumier P.

Int J Immunopathol Pharmacol. 2010 Jan-Mar;23(1):121-9.

PMID:
20378000
11.

A subchronic murine intravenous pharmacokinetic and toxicity study of Hematide™, a PEGylated peptidic erythropoiesis-stimulating agent.

Woodburn KW, Fan Q, Schatz PJ, Wilson SD, Fong KL, Norton D.

Drug Chem Toxicol. 2010 Jan;33(1):28-37. doi: 10.3109/01480540903176610.

PMID:
19995307
12.

High-affinity FGFR2 binding peptides derived from the native epitope of the KGF ligand.

Pan Y, Angell YM, Green JM, Wright KL, Miguel J, Schatz PJ, Holmes CP.

Adv Exp Med Biol. 2009;611:511-2. No abstract available.

PMID:
19400289
13.

Discovery and optimization of a TRAIL R2 agonist for cancer therapy.

Angell YM, Bhandari A, De Francisco MN, Frederick BT, Green JM, Leu K, Leuther K, Sana R, Schatz PJ, Whitehorn EA, Wright K, Holmes CP.

Adv Exp Med Biol. 2009;611:101-3. No abstract available.

PMID:
19400112
14.

Chronic pharmacological and safety evaluation of Hematide, a PEGylated peptidic erythropoiesis-stimulating agent, in rodents.

Woodburn KW, Wilson SD, Fong KL, Schatz PJ, Spainhour CB, Norton D.

Basic Clin Pharmacol Toxicol. 2009 Feb;104(2):155-63. doi: 10.1111/j.1742-7843.2008.00347.x.

PMID:
19143750
15.

Chronic preclinical safety evaluation of Hematide, a pegylated peptidic erythropoiesis stimulating agent in monkeys.

Woodburn KW, Wilson SD, Fong KL, Schatz PJ, Ferrell T, Spainhour CB, Norton D.

Haematologica. 2008 Sep;93(9):1376-9. doi: 10.3324/haematol.12896.

PMID:
18519511
16.

Designing better coumarin-based fluorogenic substrates for PTP1B.

Holmes CP, Macher N, Grove JR, Jang L, Irvine JD.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3382-5. doi: 10.1016/j.bmcl.2008.04.021.

PMID:
18442911
17.

PTP1B inhibitors: synthesis and evaluation of difluoro-methylenephosphonate bioisosteres on a sulfonamide scaffold.

Holmes CP, Li X, Pan Y, Xu C, Bhandari A, Moody CM, Miguel JA, Ferla SW, De Francisco MN, Frederick BT, Zhou S, Macher N, Jang L, Irvine JD, Grove JR.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2719-24. doi: 10.1016/j.bmcl.2008.03.007.

PMID:
18372175
18.

Preclinical safety and pharmacology of Hematide, a peptidic erythropoiesis stimulating agent (ESA), in rats and monkeys.

Woodburn KW, Schatz PJ, Fong KL, Wilson SD, Ferrell T, Spainhour CB, Norton D.

Drug Chem Toxicol. 2008;31(2):229-44. doi: 10.1080/01480540701873186 .

PMID:
18330784
19.

Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model.

Woodburn KW, Fan Q, Winslow S, Chen MJ, Mortensen RB, Casadevall N, Stead RB, Schatz PJ.

Exp Hematol. 2007 Aug;35(8):1201-8.

PMID:
17662888
20.

Npas4, a novel helix-loop-helix PAS domain protein, is regulated in response to cerebral ischemia.

Shamloo M, Soriano L, von Schack D, Rickhag M, Chin DJ, Gonzalez-Zulueta M, Gido G, Urfer R, Wieloch T, Nikolich K.

Eur J Neurosci. 2006 Nov;24(10):2705-20.

PMID:
17156197
Items per page

Supplemental Content

Loading ...
Support Center